EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preliminary Findings of the EPIRUS Familial Hypercholesterolemia Reverse Cascade Program for Pediatric Targeted Screening

Aikaterini Nikolaou, Charilaos Kostoulas, Eleana Hatzidaki, Ioannis Papasotiriou, Ioanna Thoma, Anastasios Serbis, Fotios Barkas, Antonios Vlahos, Haralampos Milionis

Journal of Atherosclerosis Prevention and Treatment · 2026-01 · 17 (1) · 22-28

DOI: 10.4103/aptj.aptj_29_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Atherosclerosis Prevention and Treatment, online erschienen am 13.07.2026. Verfasst von Aikaterini Nikolaou und 8 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Familial hypercholesterolemia (FH) causes lifelong elevation of low-density lipoprotein cholesterol (LDL-C) and increases the risk of premature cardiovascular disease (CVD). Despite effective therapies, FH remains substantially underdiagnosed worldwide.

Objective

To evaluate the diagnostic yield and clinical characteristics of targeted pediatric FH screening within the EPIRUS FH reverse cascade project. Materials and Methods: This observational cohort study evaluated children aged 4–16 years in a regional screening program in Northwestern Greece. Eligibility included LDL-C ≥160 mg/dL, LDL-C ≥130 mg/dL with a family history of hyperlipidemia or premature CVD, or lipid-lowering therapy use for suspected FH. Biochemical evaluation and next-generation sequencing (LDL receptor [ LDLR ], apolipoprotein B [ ApoB ], and proprotein convertase subtilisin/kexin type 9 [ PCSK9 ]) were performed to determine genetic diagnostic yield, pathogenic variant distribution, and clinical associations with genetic positivity.

Results

Among 230 participants (mean age 9.37 years), 60% had genetically confirmed FH, 37% tested negative, and 3% had variants of uncertain significance. Three participants were homozygous for FH. Pathogenic variants primarily occurred in LDLR (92%), followed by ApoB (6%) and PCSK9 ( 2%). Genetically positive children exhibited significantly higher LDL-C (mean difference + 56.16 mg/dL, P = 0.001) and total cholesterol (+48.50 mg/dL, P = 0.003), and more frequently reported a family history of premature CVD (61.5% vs. 40.3%, P = 0.005).

Conclusions

Targeted pediatric screening combined with genetic testing achieves a high diagnostic yield in clinically selected pediatric populations. The EPIRUS FH project demonstrates the feasibility of integrating pediatric testing into routine clinical practice for early detection and family-based reverse cascade screening.

Zitieren

APA

Nikolaou, A., Kostoulas, C., Hatzidaki, E., Papasotiriou, I., Thoma, I., Serbis, A., Barkas, F., Vlahos, A., & Milionis, H. (2026). Preliminary Findings of the EPIRUS Familial Hypercholesterolemia Reverse Cascade Program for Pediatric Targeted Screening. Journal of Atherosclerosis Prevention and Treatment, 17(1), 22-28. https://doi.org/10.4103/aptj.aptj_29_26

Vancouver

Nikolaou A, Kostoulas C, Hatzidaki E, Papasotiriou I, Thoma I, Serbis A, et al. Preliminary Findings of the EPIRUS Familial Hypercholesterolemia Reverse Cascade Program for Pediatric Targeted Screening. Journal of Atherosclerosis Prevention and Treatment. 2026;17(1):22-28. doi:10.4103/aptj.aptj_29_26

BibTeX
@article{Nikolaou2026,
  author = {Nikolaou, Aikaterini and Kostoulas, Charilaos and Hatzidaki, Eleana and Papasotiriou, Ioannis and Thoma, Ioanna and Serbis, Anastasios and Barkas, Fotios and Vlahos, Antonios and Milionis, Haralampos},
  title = {Preliminary Findings of the EPIRUS Familial Hypercholesterolemia Reverse Cascade Program for Pediatric Targeted Screening},
  journal = {Journal of Atherosclerosis Prevention and Treatment},
  year = {2026},
  volume = {17},
  number = {1},
  pages = {22--28},
  doi = {10.4103/aptj.aptj_29_26}
}
Kostenlos starten →